ICCC Q3 2025 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-8.4% YoY

Gross Profit

$2M42.9% margin

Operating Income

$20,0750.4% margin

Net Income

-$139,748-2.5% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-14.6%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$73,161

Balance Sheet

Total Assets

$46M

Total Liabilities

$16M

Stockholders' Equity

$30M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$6M	-8.4%
Gross Profit	$2M	$2M	+49.2%
Operating Income	$20,075	-$574,894	+103.5%
Net Income	-$139,748	-$701,690	+80.1%